Tuyory
Tocilizumab biosimilar developed by Gedeon Richter, development code RGB-19. Reference product Actemra (RoActemra in the European Union).
Brands by market: Tuyory (EU) · Commercial partner or holder: Gedeon Richter
FDAnot listed
EMAApr 2026authorised
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Tuyory
European Medicines Agency and European CommissionApprovedBrand
Tuyory
Holder or applicant
Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
Pathway
Centralised (Article 10(4))
Approved
Apr 2026
Application or permission
EMEA/H/C/006416
Presentations
see SmPC
Source
S017
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- EMAApr 2026Authorised by the European Commission
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning tocilizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.